कंपनी का अवलोकन
Ainos, Inc. (AIMD) operates as a dual-platform enterprise integrating artificial intelligence and biotechnology sectors, specifically targeting the scientific and technical instruments industry through its SmellTech, AI diagnostics, and immune therapeutics initiatives. The firm's core technological offering involves an AI Nose platform that utilizes a specialized smell language model to digitize olfactory signals into Smell IDs, effectively converting invisible chemical data into machine-readable formats for diagnostic applications. As of the latest reporting period, the company maintains a market capitalization of $12.28M and employs a workforce of 41 individuals to support its R&D and operational infrastructure. The annual revenue generated over the trailing twelve months stands at $124,157, which, when juxtaposed against a market cap of $12.28M, indicates a valuation structure that significantly exceeds current book value and sales multiples, reflecting high market expectations or speculative pricing common in early-stage technology firms with limited historical financial track records.
वित्तीय स्वास्थ्य
The company reported a revenue of $124,157 for the trailing twelve months, while simultaneously posting a net income of -$14,771,012 and an EBITDA of -$9,210,258. The substantial disparity between the positive revenue figure and the massive negative net income reveals a highly aggressive cost structure where operating expenses, likely driven by heavy research and development investments in AI and biotech, far exceed current earnings. Despite the significant net losses, the company generated positive free cash flow of $52,412, suggesting that core operational activities are currently generating liquidity even while the broader income statement reflects non-cash or heavy fixed costs. The gross margin stands at 82.9%, indicating that the cost of goods sold is relatively low compared to sales, yet the operating margin is reported at -38,648.0% and the profit margin is 0.0%, figures that highlight extreme operational inefficiency or accounting anomalies where operating expenses dwarf revenue entirely. On the liability side, the company holds $417,353 in cash against $11.00M in debt, resulting in a debt-to-equity ratio of 145.45%, which signifies a highly leveraged balance sheet where debt obligations substantially exceed shareholder equity. The current ratio is calculated at 1.06, implying that the company's current assets barely cover its current liabilities, indicating a precarious short-term liquidity position with minimal buffer against immediate obligations. Furthermore, the return on equity is -128.0% and the return on assets is -35.2%, metrics that demonstrate that management's effectiveness in generating profit from the capital invested by shareholders and the total asset base is currently negative, eroding value rather than creating it in the current fiscal period.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A, a status that implies the market cannot value the stock based on historical or expected earnings per share due to the absence of positive net income. In the absence of a P/E metric, the price-to-book ratio serves as a primary valuation gauge, standing at 1.31, which indicates that the stock trades at a 31% premium over its book value despite the company's significant losses. Alternative valuation metrics provide further insight, with the price-to-sales ratio at 98.90% and an EV/EBITDA of -2.48, suggesting that the market is willing to pay nearly equal to sales revenue for the company, a multiple often seen in growth-oriented biotech or AI firms where future potential outweighs current profitability. The stock has exhibited significant volatility over the past year, with a 52-week high of $4.50 and a 52-week low of $1.26, and the current trading price sits within this range but closer to the lower end given the negative earnings environment. The beta value is recorded at 2.32, indicating that the stock price is expected to fluctuate with 2.32 times the volatility of the broader market, making it a high-risk investment suitable for investors with high tolerance for price swings relative to standard equity benchmarks.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is insufficient historical data within the provided facts to calculate a growth rate or determine if earnings are expanding faster than sales. Consequently, it is impossible to assess the sustainability of a dividend yield or payout ratio as both are currently N/A and 0.0% respectively, confirming that the company does not distribute income to shareholders and retains all earnings. Instead of paying dividends, the company's strategy aligns with the industry standard for loss-making biotech and AI firms, which reinvest limited cash flow of $52,412 directly back into growth initiatives such as developing the Smell language model and expanding the AI Nose platform. The overall growth and income profile is characterized by a lack of historical earnings growth data and a complete absence of dividend income, reflecting a capital-intensive business model focused on long-term technological milestones rather than immediate shareholder returns.